Drug Profile
Research programme: cancer immunotherapeutics - CARsgen
Alternative Names: CSG-002; CSG-004; CSG-005; CSG-007Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator CARsgen
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Gastric cancer; Glioblastoma; Neuroblastoma; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Gastric-cancer in China (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Glioblastoma in China (Parenteral)